Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases
Shots:
- Anima to receive ~ $120M up front- preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under the collaboration
- Takeda gets an exclusive right to develop and commercialize the mRNA transational modulators and has a time limited option to expands the collaboration for three additional targets for which Anima will receive additional payments including ~$1.2B as milestones and royalties
- Anima will leverage its translation control therapeutics platform to discover novel mRNA translation modulators against the collaboration targets
Ref: GlobeNewswire | Image: GlobeNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com